A Phase 2 interventional study of AZD2281 in Ovarian Carcinoma and Breast Cancer, sponsored by AstraZeneca. Completed at 6 sites in Canada. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2023-07-12.
Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.
Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 32nd largest by enrollment, is one of 4 that started in 2008, is one of 32 in phase 2, and was the 5th registered.
3,390 studies on the registry are indexed under Ovarian Neoplasms; 791 are open to participants now.
Browse Ovarian Neoplasms studies →13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:
Bai-Rong Xia · Sites in China
Ages 18–75 · Women only
Daewoong Pharmaceutical Co. LTD. · Sites in Korea, Republic of
Ages 19+ · Women only
Boryung Pharmaceutical Co., Ltd · Sites in Korea, Republic of
Ages 19–74 · Women only
The Netherlands Cancer Institute · Sites in Netherlands
Ages 18–100 · Women only
NRG Oncology · Sites in United States, Japan, Puerto Rico
Ages 18+
By country, each count listing its studies:
olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 602 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.
This study: 18 Years to 130 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, olaparib is the treatment under test here. Read study by study →
69 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 17 · Phase 4 3
First in 2005; this study’s year is marked. 4 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 99 is above the median of 54 across 2,556 interventional studies indexed under Ovarian Neoplasms.
Median enrollment 96 across the 69 interventional studies. Of the 33 that completed or were terminated, 16 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 69 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,505 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
70 studies in Ovarian Neoplasms by AstraZeneca: 8 open now, 20 under way, 6 of them phase 3. Of 45 finished, 15 (33%) have results posted.
Among the 70 studies in Ovarian Neoplasms by AstraZeneca, this one is the 27th largest by enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2008, is one of 12 in phase 2, and was the 8th registered.
AstraZeneca’s Ovarian Neoplasms studies by the year they started, since 2001.
5 of the studies testing olaparib in Ovarian Neoplasms that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04421963Phase 3AstraZenecaRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib | 2027-04-06 |
| NCT03579316M.D. Anderson Cancer CenterAdavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | 2026-12-31 |
| NCT07371104Daewoong Pharmaceutical Co. LTD.Bioequivalence Study of DWZ2501 in Patients With Advanced BRCA-mutated High-grade Ovarian Cancer | 2027-03 |
| NCT07460180The Netherlands Cancer InstituteThe PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery and HIPEC in Ovarian Cancer | 2027-05-01 |
| NCT03943173M.D. Anderson Cancer CenterOlaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery | 2027-06-27 |
Add all 5 to your calendar (.ics) → With an account.
Among the 69 studies testing olaparib in Ovarian Neoplasms, from their registry updates:
Among AstraZeneca’s 70 in Ovarian Neoplasms:
This tab as a report to print or save as PDF → With an account.
This is a Phase II, open label, non randomized correlative study of AZD2281 in patients with recurrent breast and ovarian cancer in both BRCA inherited mutation carriers and non-carriers to identify objective response rate and to assess for early markers of activity and to assess correlative markers that may provide helpful information for subsequent clinical trials. Approximately 110 patients from 7 centers in Canada will be enrolled into this study
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Triple negative breast Cancer with unknown BRCA mutation status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally AZD2281, PARP inhibitor Olaparib tablets, oral
Drug: AZD2281
Known BRCA mutation positive breast cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) to be administered orally AZD2281, PARP inhibitor Olaparib tablets, oral
Drug: AZD2281
High grade serous/undifferentiated tubo-ovarian carcinoma with unknown BRCA status: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally AZD2281, PARP inhibitor Olaparib tablets, oral
Drug: AZD2281
Known BRCA mutation positive ovarian cancer: AZD2281 400 mg bid (capsules)/ 300 mg bid (tablets) administered orally AZD2281, PARP inhibitor Olaparib tablets, oral
Drug: AZD2281
PARP inhibitor Olaparib tablets, oral
Also known as: Olaparib
Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines
Percentage of participants with confirmed best RECIST response of complete response (CR) or partial response (PR). Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.
Time frame: Each patient with measurable disease at baseline was assessed for Objective Response from the sequence of RECIST scan data up to data cut-off, 26 March 2010. RECIST scans were performed every 8 weeks (+/- 2 weeks) from randomization.
Disease Control Rate (DCR)
Percentage of participants with confirmed best Response Evaluation Criteria In Solid Tumours (RECIST) response of complete response (CR), partial response (PR) orStable Disease (SD)
Time frame: 16 Weeks
Duration of Response
Duration of response is measured from the time the measurement criteria for CR or PR are met (whichever is first recorded) until the patient progresses (per RECIST criteria). If patient did not progress, they are censored at their last objective tumour assessment date.
Time frame: RECIST tumour assessments carried out every 8 weeks from randomization (+/- 2 weeks) until data cut-off on 26 March 2010.
Best Percentage Change From Baseline in Tumour Size
The best percentage change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).
Time frame: Each patient with measurable disease at baseline was assessed for best percentage change in tumour size from the sequence of RECIST scan data up to data cut-off, 26 March 2010. RECIST scans were performed every 8 weeks (+/- 2 weeks) from randomization.
CA-125 Levels (Ovarian Cancer Patients Only)
A response according to CA-125 has occurred if there is at least a 50% reduction in CA-125 levels from a pre-treatment sample.
Time frame: 24 weeks
Progression Free Survival (PFS)
PFS is defined as the time from first dose to the earlier date of radiologic progression (as per Response Evaluation Criteria In Solid Tumours (RECIST) criteria or death by any cause in the absence of objective progression.
Time frame: RECIST tumour assessments carried out every 8 weeks from randomization (+/- 2 weeks) until data cut-off on 26 March 2010.
The first patient was enrolled on July 8, 2008 and efficacy and safety data were collected up to the data cut-off of March 26, 2010. Patients were enrolled at 6 centres in Canada. Of the 112 patients who gave informed consent 21 patients failed eligibility criteria or withdrew their consent and were not allocated to treatment.
| Milestone | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| Started | 4 | 13 | 3 | 45 | 5 | 5 | 16 |
| Completed | 2 | 10 | 2 | 25 | 4 | 5 | 15 |
| Not completed | 2 | 3 | 1 | 20 | 1 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 3 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 2 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 1 | 0 | 0 | 0 |
| Withdrew: Not captured | 0 | 0 | 0 | 5 | 0 | 0 | 0 |
| Withdrew: Ongoing at data cut-off | 2 | 2 | 0 | 9 | 1 | 0 | 0 |
Percentage of participants with confirmed best RECIST response of complete response (CR) or partial response (PR). Patients with a best RECIST response of CR or PR had to have a confirmed response at least 28 days later.
| Percentage of participants | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| Objective Response Rate (ORR) Evaluated According to Response Evaluation Criteria In Solid Tumors (RECIST) Guidelines | 75 (30.06 to 95.44) | 30.77 (12.68 to 57.63) | 0 (0 to 56.15) | 25.58 (14.93 to 40.24) | 0 (0 to 48.99) | 0 (0 to 48.99) | 0 (0 to 20.39) |
Percentage of participants with confirmed best Response Evaluation Criteria In Solid Tumours (RECIST) response of complete response (CR), partial response (PR) orStable Disease (SD)
| Percentage of participants | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| Disease Control Rate (DCR) | 75 (30.06 to 95.44) | 53.85 (29.14 to 76.79) | 0 (0 to 56.15) | 47.73 (33.75 to 62.06) | 60 (23.07 to 88.24) | 20 (3.62 to 62.45) | 0 (0 to 19.36) |
Duration of response is measured from the time the measurement criteria for CR or PR are met (whichever is first recorded) until the patient progresses (per RECIST criteria). If patient did not progress, they are censored at their last objective tumour assessment date.
| Days | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| Duration of Response | 277 (261 to 504) | 113 (109 to 446) | — | 384 (105 to 396) | — | — | — |
The best percentage change (reduction) from baseline in tumour size (defined as the sum of the longest diameters as measured among all target lesions).
| Percentage | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| Best Percentage Change From Baseline in Tumour Size | -44.5 (-64 to 4) | -21.6 (-100 to 16) | 33.6 (14 to 53) | -14.1 (-95 to 83) | -35.3 (-48 to 10) | -36.4 (-50 to 11) | 21.3 (-3 to 50) |
A response according to CA-125 has occurred if there is at least a 50% reduction in CA-125 levels from a pre-treatment sample.
| Percentage of participants | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| CA-125 Levels (Ovarian Cancer Patients Only) | 75 (30.06 to 95.44) | 33.33 (13.81 to 60.94) | 0 (0 to 56.15) | 28.57 (16.33 to 45.05) | — | — | — |
PFS is defined as the time from first dose to the earlier date of radiologic progression (as per Response Evaluation Criteria In Solid Tumours (RECIST) criteria or death by any cause in the absence of objective progression.
| Days | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 346.5 (51 to 553) | 219 (1 to 503) | 79.5 (1 to 109) | 192 (1 to 559) | 165 (53 to 168) | 106 (37 to 277) | 54 (1 to 111) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BRCA Positive Non-serous Ovarian | — | 0/4 (0%) | 4/4 (100%) |
| BRCA Positive Serous Ovarian | — | 4/13 (30.8%) | 13/13 (100%) |
| BRCA Negative Non-serous Ovarian | — | 0/3 (0%) | 3/3 (100%) |
| BRCA Negative Serous Ovarian | — | 6/44 (13.6%) | 44/44 (100%) |
| BRCA Positive Non-triple Negative Breast | — | 0/5 (0%) | 5/5 (100%) |
| BRCA Positive Triple Negative Breast | — | 2/5 (40%) | 5/5 (100%) |
| BRCA Negative Triple Negative Breast | — | 2/16 (12.5%) | 15/16 (93.8%) |
| Event | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/4 | 0/13 | 0/3 | 0/44 | 0/5 | 1/5 | 0/16 |
| Pleural InfectionInfections and infestations | 0/4 | 0/13 | 0/3 | 0/44 | 0/5 | 1/5 | 0/16 |
| DehydrationMetabolism and nutrition disorders | 0/4 | 0/13 | 0/3 | 0/44 | 0/5 | 1/5 | 0/16 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 0/4 | 0/13 | 0/3 | 0/44 | 0/5 | 1/5 | 0/16 |
| Pulmonary EmbolismRespiratory, thoracic and mediastinal disorders | 0/4 | 0/13 | 0/3 | 0/44 | 0/5 | 1/5 | 0/16 |
| HaematemesisGastrointestinal disorders | 0/4 | 1/13 | 0/3 | 0/44 | 0/5 | 0/5 | 0/16 |
| Haemoglobin DecreasedInfections and infestations | 0/4 | 1/13 | 0/3 | 0/44 | 0/5 | 0/5 | 0/16 |
| Back PainMusculoskeletal and connective tissue disorders | 0/4 | 1/13 | 0/3 | 0/44 | 0/5 | 0/5 | 0/16 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/4 | 1/13 | 0/3 | 0/44 | 0/5 | 0/5 | 1/16 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 0/4 | 0/13 | 0/3 | 0/44 | 0/5 | 0/5 | 1/16 |
| Event | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast |
|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 3/4 | 9/13 | 2/3 | 28/44 | 3/5 | 5/5 | 8/16 |
| FatigueGeneral disorders | 4/4 | 12/13 | 1/3 | 28/44 | 3/5 | 3/5 | 7/16 |
| HeadacheNervous system disorders | 3/4 | 2/13 | 0/3 | 7/44 | 3/5 | 0/5 | 2/16 |
| VomitingGastrointestinal disorders | 2/4 | 4/13 | 1/3 | 18/44 | 2/5 | 3/5 | 4/16 |
| Decreased AppetiteMetabolism and nutrition disorders | 2/4 | 7/13 | 1/3 | 13/44 | 2/5 | 1/5 | 4/16 |
| Abdominal DistensionGastrointestinal disorders | 2/4 | 3/13 | 0/3 | 11/44 | 0/5 | 0/5 | 1/16 |
| DiarrhoeaGastrointestinal disorders | 2/4 | 2/13 | 0/3 | 11/44 | 0/5 | 0/5 | 0/16 |
| Abdominal Pain UpperGastrointestinal disorders | 2/4 | 2/13 | 0/3 | 5/44 | 1/5 | 0/5 | 0/16 |
| StomatitisGastrointestinal disorders | 2/4 | 2/13 | 0/3 | 1/44 | 1/5 | 0/5 | 1/16 |
| Oedema PeripheralGeneral disorders | 2/4 | 3/13 | 0/3 | 8/44 | 0/5 | 0/5 | 2/16 |
| Age, Continuous(Year) | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast | Total |
|---|---|---|---|---|---|---|---|---|
| Mean | 60 ± 18.7 | 53.7 ± 7.3 | 60.3 ± 12.9 | 61 ± 9.5 | 49.4 ± 20.5 | 44.8 ± 15.5 | 48.8 ± 5.5 | 52.9 ± 13 |
| Sex: Female, Male(Participants) | BRCA Positive Non-serous Ovarian | BRCA Positive Serous Ovarian | BRCA Negative Non-serous Ovarian | BRCA Negative Serous Ovarian | BRCA Positive Non-triple Negative Breast | BRCA Positive Triple Negative Breast | BRCA Negative Triple Negative Breast | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 4 | 13 | 3 | 44 | 5 | 5 | 16 | 90 |
| Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com
Ran from Jul 2008 to primary completion in Mar 2010, 20 months.
Results were first posted in Aug 2011, 1 year 4 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Ovarian Neoplasms, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 51. This study's 20 months is below that.
Counting every sponsor, half of 344 studies reached it within 47 months; a quarter within 33 and three quarters within 72.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Olaparib